Dr. Brian T. Halbert, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1514 Jefferson Hwy
New Orleans, LA 70121
Who else practices at this address →
Jefferson Parish includes primary care (18% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 146
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Tulane University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
LA license 331370 -
Hospitalist Physician
MA license 259072 -
Internal Medicine Physician
MA license 259072
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- Ochsner Medical Center - Baton Rouge Baton Rouge, LA
- Ochsner Medical Center-Kenner Kenner, LA
- St Charles PArish Hospital Luling, LA
- St Bernard PArish Hospital Chalmette, LA
Medical groups
- Ochsner Clinic LLC (2,864 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 146
- Services billed
- 742
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 180 | 53 |
| Established patient office or other outpatient visit, 30-39 minutes | 53 | 38 |
| New patient office or other outpatient visit, 60-74 minutes | 45 | 45 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in New Orleans, LA | 317 |
| Abiraterone Acetate | 233 |
| Erleada (apalutamide) | 96 |
| Nubeqa (darolutamide) | 89 |
| Tamsulosin Hcl Other prescribers in New Orleans, LA | 66 |
| Amlodipine Besylate Other prescribers in New Orleans, LA | 56 |
| Furosemide Other prescribers in New Orleans, LA | 55 |
| Oxycodone Hcl Other prescribers in New Orleans, LA | 52 |
| Prochlorperazine Maleate Other prescribers in New Orleans, LA | 48 |
| Cabometyx (cabozantinib s-malate) | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 24 payments worth $7,512 in total to this clinician.
| Eisai Inc. | $2,504 |
|---|---|
| Astellas Pharma US Inc | $1,826 |
| Janssen Biotech, Inc. | $1,263 |
| Bayer HealthCare Pharmaceuticals Inc. | $890 |
| Janssen Scientific Affairs, LLC | $579 |
| Pfizer Inc. | $337 |
| Beone Medicines USA, Inc. | $40.40 |
| Progenics Pharmaceuticals, Inc. | $32.34 |
| Consulting Fee | $6,353 |
|---|---|
| Food and Beverage | $1,159 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Jul 23, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Astellas Pharma US Inc Nov 19, 2025 | Consulting Fee Padcev · Oncology | $1,800 |
| Janssen Biotech, Inc. May 23, 2025 | Consulting Fee ERLEADA · Oncology | $1,263 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 13, 2025 | Consulting Fee Xofigo · Oncology | $890 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $40,151 in research payments for these studies, mostly to the institutions running them.
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company · Recruiting · NCT05614739 - MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With …
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.